Dr. Ronit Simantov M.D. serves as Chief Medical Officer of the Company. Dr. Simantov has more than 20 years of experience in in hematology and oncology research, development, registration and product launch. Prior to joining Gamida Cell, from 2011 to 2017, Dr. Simantov served as head of oncology global medical affairs at Pfizer, where she was responsible for multiple programs including Sutent (sunitinib), Inlyta (axitinib), Ibrance (palbociclib), Bosulif (bosutinib), and Xalkori(crizotinib). From 2010 to 2011, Dr. Simantov led Phase 1 through Phase 3 studies as Vice President of Clinical Research at OSI Pharmaceuticals. Dr. Simantov also led development of small molecules and antibody-drug conjugates at CuraGen Corporation (acquired by Celldex) from 2007-2009, where she served as Chief Medical Officer. Prior to joining industry, Dr. Simantov spent seven years on the academic faculty at Weill Medical College of Cornell University, where she directed the fellowship program and conducted angiogenesis and vascular biology research. She has authored over 40 peer-reviewed manuscripts. Dr. Simantov earned a B.A. from Johns Hopkins University and an M.D. from New York University School of Medicine. She completed a residency in internal medicine at New York Presbyterian Hospital and a fellowship in hematology and oncology at Weill Cornell Medicine.
As the Chief Medical Officer of Gamida Cell Ltd, the total compensation of Ronit Simantov at Gamida Cell Ltd is $912,000. There are 1 executives at Gamida Cell Ltd getting paid more, with Julian Adams having the highest compensation of $2,232,000.
Ronit Simantov is 55, he's been the Chief Medical Officer of Gamida Cell Ltd since 2017. There are 9 older and 12 younger executives at Gamida Cell Ltd. The oldest executive at Gamida Cell Ltd is Dr. Julian Adams Ph.D., 66, who is the CEO & Director.
Ronit's mailing address filed with the SEC is C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON, MA, 02116.
Over the last 3 years, insiders at Gamida Cell Ltd have traded over $0 worth of Gamida Cell Ltd stock and bought 85,483 units worth $132,499 . The most active insiders traders include Stephen T Wills, Robert I Blum oraz Jeremy Blank. On average, Gamida Cell Ltd executives and independent directors trade stock every 0 days with the average trade being worth of $699. The most recent stock trade was executed by Stephen T Wills on 30 September 2022, trading 9,677 units of GMDA stock currently worth $14,999.
gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.
Gamida Cell Ltd executives and other stock owners filed with the SEC include: